Mach Markus, Koschutnik Matthias, Wilbring Manuel, Winkler Bernhard, Reinweber Matthias, Alexiou Konstantin, Kappert Utz, Adlbrecht Christopher, Delle-Karth Georg, Grabenwöger Martin, Matschke Klaus Ehrhard
Department of Cardiovascular Surgery, Heart Team Vienna, Hospital Hietzing and the Karl Landsteiner Institute for Cardiovascular Research, Vienna, Austria.
Division of Cardiac Surgery, Medical University of Graz, Austria.
Thorac Cardiovasc Surg. 2019 Jun;67(4):251-256. doi: 10.1055/s-0039-1685177. Epub 2019 Apr 4.
The purpose of this study was to evaluate the impact of chronic obstructive pulmonary disease (COPD) on clinical outcomes in patients referred for transfemoral (TF) as well as transapical (TA) aortic valve implantation and furthermore to delineate possible advantages of the TF access.
One thousand eight hundred forty-two patients undergoing transcatheter aortic valve implantation (TAVI) at two study centers were included in the present analysis. The outcome was measured and classified according to Valve Academic Research Consortium-II criteria. Kaplan-Meier estimate was used to assess long-term survival.
The present analysis suggests that COPD has limited influence on post-procedural outcome after TAVI. Comparing the TF to TA approach, no significant difference on the impact of COPD on clinical outcomes has been found, except for longer post-procedural ventilation times in COPD patients treated via TA access ( < 0.001).
COPD in patients referred for TAVI procedure was associated with poorer overall long-term survival, thus characterizing a high-risk population for futile treatment; however, the selection of access did not result in a significant difference in most Valve Academic Research Consortium-II-defined clinical outcomes in COPD patients.
本研究旨在评估慢性阻塞性肺疾病(COPD)对接受经股动脉(TF)及经心尖(TA)主动脉瓣植入术患者临床结局的影响,并进一步阐明经股动脉入路可能存在的优势。
本分析纳入了在两个研究中心接受经导管主动脉瓣植入术(TAVI)的1842例患者。根据瓣膜学术研究联盟-II标准对结局进行测量和分类。采用Kaplan-Meier估计法评估长期生存率。
本分析表明,COPD对TAVI术后结局的影响有限。比较经股动脉与经心尖入路,未发现COPD对临床结局的影响存在显著差异,但经心尖入路治疗的COPD患者术后通气时间更长(<0.001)。
接受TAVI手术的患者中,COPD与总体长期生存率较低相关,因此这类患者属于无效治疗的高危人群;然而,在大多数瓣膜学术研究联盟-II定义的临床结局方面,入路选择在COPD患者中并未导致显著差异。